AbbVie's head of global head of immunology discovery research says the ability to profile patients at the molecular level has the potential to dramatically change treatment for people living with chronic conditions.
New testing means patients no longer 'defined by their symptoms'
February 26, 2019 Latest NewsBioPharmaDispatch Executive
Latest Video
New Stories
-
Merck expands commitment to first nations STEM leadership with new scholarships and partnerships
October 19, 2025 - - Latest News -
Orthocell boosts balance sheet with capital raise to drive nerve repair product growth
October 19, 2025 - - Australian Biotech -
Amplia targets US market expansion as FAK inhibitor shows promise in pancreatic cancer
October 19, 2025 - - Australian Biotech -
New combination therapy sets landmark survival benchmark in bladder cancer treatment
October 19, 2025 - - Latest News -
AdvanCell unveils promising first clinical results for 212Pb-ADVC001 in prostate cancer
October 19, 2025 - - Australian Biotech -
Trump announces third MFN deal with a focus on fertility drug costs and expanding IVF access
October 18, 2025 - - Latest News -
An exceptional outcome that must not become an exception
October 18, 2025 - - Latest News